An Ebola vaccine developed in record time has proved highly effective against the deadly virus in a large trial in Guinea and could now be used to help end a vast outbreak in West Africa, researchers said on Friday.
Results of the trial, which tested Merck and NewLink Genetics' VSV-ZEBOV vaccine on more than 4,000 people who had been in close contact with a confirmed Ebola case, showed it gave 100 percent protection after 10 days in those immunized.
Publishing the results online in the medical journal The Lancet on Friday, researchers said they showed that the vaccine could be "highly efficacious in preventing Ebola virus disease".
Jeremy Farrar, a leading infectious disease specialist and director of the Wellcome Trust, which helped fund the trial, described the results as "remarkable".
We tnkGod for the break through oh...
ReplyDeleteHmmm
ReplyDeleteWe hope the vaccine will b affordable to all if possible FOC...lol
ReplyDeleteHmm..God help us all
ReplyDeleteNice1. Have u heard Nigeria's new National anthem? Anticipate #PromiseLand
ReplyDeleteThank God oo
ReplyDeleteGood work...
ReplyDelete